Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTXinGCA
2022-501058-12-00Phase 2Completed
- Sponsor
- University of Bonn
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in giant cell arteritis (GCA) comparing Methotrexate maintenance with Placebo (2 arms). Primary endpoint: Time to relapse during the 12 months treatment period. Started Nov 2022; status: completed.
02
Drugs
methotrexate
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2022-501058-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501058-12-00.